You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Mallinckrodt
McKesson
AstraZeneca
Boehringer Ingelheim

Last Updated: May 8, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SILVER SULFADIAZINE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Silver Sulfadiazine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00156988 The Effect of Two Versus Ten Days Application of Flammacerium in Partial Thickness Burns Completed Dutch Burns Foundation Phase 4 2004-03-01 The objective of the proposed study is to assess whether the application of flammacerium for 2 days is as good as, or even better than, the application of flammacerium for 10 days regarding woundhealing in partial thickness burns.
NCT00156988 The Effect of Two Versus Ten Days Application of Flammacerium in Partial Thickness Burns Completed Association of Dutch Burn Centres Phase 4 2004-03-01 The objective of the proposed study is to assess whether the application of flammacerium for 2 days is as good as, or even better than, the application of flammacerium for 10 days regarding woundhealing in partial thickness burns.
NCT00641433 Topical Collagen-Silver Versus Standard Care Following Removal of Ingrown Nails Unknown status Rosalind Franklin University of Medicine and Science N/A 2005-11-01 This study's purpose is to prospectively determine whether topical therapy with an oxidized regenerated cellulose collagen-silver compound is more effective than the current standard of topical antibiotic therapy for care following the removal of an ingrown toenail. Eighty adult patients with ingrown toenails will be recruited. Each patient will randomly be assigned to apply either topical silver sulfadiazine cream (standard antibiotic) or the novel collagen-silver compound to their nail bed daily, following removal of the ingrown portion of nail. Patients will return for follow up visits weekly, until healing has occurred or twelve weeks have passed. Healing will be defined as resolution of drainage and inflammatory changes surrounding the nail border.
NCT00798083 Neuropathic Pain Caused by Radiation Therapy Completed British Columbia Cancer Agency Phase 3 2008-04-01 To investigate if topical amitriptyline 2%, ketamine 1%, and lidocaine 5% in pluronic lecitine organogel (AKL in PLO gel) can improve management of neuropathic pain from radiation skin reactions adjunctively or better than standard treatment.
NCT01439074 An Open, Randomized, Multi-centre Investigation With Mepilex Ag Versus Silver Sulfadiazine in the Treatment of Deep Partial Thickness Burn Injuries. Completed Molnlycke Health Care AB Phase 4 2011-09-01 The purpose is to compare time to healing using absorbent foam silver dressing (Mepilex Ag) compared to a silver sulfadiazine (SSD) 1% cream in the treatment of partial thickness burn injuries.284 in-patients in 8-12 centres in China will be evaluated. Treatment period will be up to 4 weeks with either Mepilex Ag or SSD.
NCT01553708 Effect of EGF With Silver Sulfadiazine Cream Compared With Silver Zinc Sulfadiazine Cream for Treatment of Burn Wound Completed National Science and Technology Development Agency, Thailand Phase 2/Phase 3 2011-12-01 Partial thickness burn wounds are most likely to heal within 2-3 weeks mainly by mechanism of epithelialization. However, it depends on the depth of the wounds and patient condition. Infection is one of the most common complications causing delay in wound healing which might affect to quality of patient's life. Generally, the standard treatment of partial thickness burn wound is topical 1% silver sulfadiazine cream. Previous studies had been reported the broad spectrum antimicrobial activity of silver sulfadiazine cream but it did not demonstrate the accelerating effect of wound healing. Therefore, the combination of substance which can promote wound healing to topical silver sulfadiazine cream might benefit for partial thickness burn wound treatment. The objective of this study was to compare the results of partial thickness burn wound treatment at burn unit, Siriraj hospital with topical cream containing 1% silver sulfadiazine plus 6% epidermal growth factor (EGF) and 1% silver zinc sulfadiazine. The demographic data (age, sex, %body surface area burn), time of wound closure, pain and itching, dose and type of pain and itching medication, adverse effect of topical medication, some laboratory results and cost of expenses. This is the prospective, double blinded, randomize-controlled study. The sample sizes were partial thickness burn wound patients who were treated at burn unit, Siriraj hospital. Patients were allocated into 2 groups receiving treatment with either topical silver sulfadiazine plus EGF or silver zinc sulfadiazine. All parameter data were analyzed with repeated measure ANOVA and independent t-test.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Silver Sulfadiazine

Condition Name

Condition Name for Silver Sulfadiazine
Intervention Trials
Burns 4
Burn 2
Wound Infection 1
Ingrown Nail 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Silver Sulfadiazine
Intervention Trials
Burns 11
Wounds and Injuries 2
Wound Infection 1
Nails, Ingrown 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Silver Sulfadiazine

Trials by Country

Trials by Country for Silver Sulfadiazine
Location Trials
China 6
United States 5
Brazil 3
Thailand 1
Belgium 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Silver Sulfadiazine
Location Trials
Virginia 2
Pennsylvania 1
Kentucky 1
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Silver Sulfadiazine

Clinical Trial Phase

Clinical Trial Phase for Silver Sulfadiazine
Clinical Trial Phase Trials
Phase 4 5
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Silver Sulfadiazine
Clinical Trial Phase Trials
Completed 10
Not yet recruiting 4
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Silver Sulfadiazine

Sponsor Name

Sponsor Name for Silver Sulfadiazine
Sponsor Trials
Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara 3
James Graham Brown Cancer Center 1
Pherecydes Pharma 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Silver Sulfadiazine
Sponsor Trials
Other 20
Industry 2
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Boehringer Ingelheim
McKesson
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.